Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial | Zendy

FrançoisClément Bidard | Zendy; Virginia Kaklamani | Zendy; Patrick Neven | Zendy; Guillermo Streich | Zendy; Alberto J. Montero | Zendy; Frédéric Forget | Zendy; MarieAnge MouretReynier | Zendy; Joohyuk Sohn | Zendy; Donatienne Taylor | Zendy; Kathleen Harnden | Zendy; Hung T. Khong | Zendy; Judit Kocsis | Zendy; Florence Dalenc | Zendy; Patrick M. Dillon | Zendy; Sunil Babu | Zendy; Simon Waters | Zendy; Ines Deleu | Zendy; José Á. García-Sáenz | Zendy; Emilio Bria | Zendy; Marina Elena Cazzaniga | Zendy; Janice Lu | Zendy; Philippe Aftimos | Zendy; Javier Cortés | Zendy; Shubin Liu | Zendy; Giulia Tonini | Zendy; Dirk Laurent | Zendy; Nassir Habboubi | Zendy; Maureen G. Conlan | Zendy; Aditya Bardia | Zendy

Open Access

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author(s) -

FrançoisClément Bidard,

Virginia Kaklamani,

Patrick Neven,

Guillermo Streich,

Alberto J. Montero,

Frédéric Forget,

MarieAnge MouretReynier,

Joohyuk Sohn,

Donatienne Taylor,

Kathleen Harnden,

Hung T. Khong,

Judit Kocsis,

Florence Dalenc,

Patrick M. Dillon,

Sunil Babu,

Simon Waters,

Ines Deleu,

José Á. García-Sáenz,

Emilio Bria,

Marina Elena Cazzaniga,

Janice Lu,

Philippe Aftimos,

Javier Cortés,

Shubin Liu,

Giulia Tonini,

Dirk Laurent,

Nassir Habboubi,

Maureen G. Conlan,

Aditya Bardia

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.22.00338

Subject(s) - medicine , hazard ratio , estrogen receptor , breast cancer , oncology , adverse effect , fulvestrant , metastatic breast cancer , cancer , endocrinology , gastroenterology , confidence interval

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research